Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

NCT06809426 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

PSMA PET-Positive Castration-Resistant Prostate Cancer

Interventions

DRUG: 177Lu-LNC1011

Sponsor

Affiliated Hospital of Jiangnan University